Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC By Ogkologos - July 7, 2025 713 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance... November 7, 2025 Inequalities cause 2,000 extra cancer cases in Wales June 8, 2023 More Than 25 Additional Years Needed to Slow an Increasing Incidence... September 8, 2021 What to Know About Cancer Clinical Trial Matching Programs March 14, 2023 Load more HOT NEWS Significant Intracranial Efficacy and Survival Benefits of Osimertinib in Patients with... Neoadjuvant Toripalimab Combined with Axitinib Demonstrates a Promising Pathologic Response Rate... Fostering Black leadership in cancer research Incidence of Colorectal, Breast, Kidney, Pancreatic, and Uterine Cancers is Increasing...
